Skip to main
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 46%
Sell 0%
Strong Sell 0%

Bulls say

Bausch & Lomb is well-positioned for future growth with strong performance in the SiHy lens and premium intraocular lens markets, as well as a promising pipeline of new products. The company's separation from Bausch Health in 2022 allows for a focused approach to eyecare and potential expansion in global markets. With a successful CFO and a new product in development, Bausch & Lomb has the potential to continue its revenue growth in the coming years.

Bears say

Bausch & Lomb is facing several fundamental risks that may negatively impact its future growth and profitability. Weak consumer demand and the company's exposure to broader economic conditions may lead to lower sales volumes and revenue. Additionally, the company's high valuation and ownership stake by parent company Bausch Health may continue to be a hindrance to its stock performance. While Bausch & Lomb's diverse portfolio and expansion in areas such as premium intraocular lenses and ophthalmic pharmaceuticals provide some growth potential, any underperformance in key areas such as MIEBO sales or contact lens demand could lead to a downward revision of revenue expectations.

BLCO has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 46% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Buy based on their latest research and market trends.

According to 13 analysts, BLCO has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.